What is the appropriate diagnostic work‑up and treatment for arterial compression causing leg numbness?

Arterial Compression Causing Leg Numbness: Diagnostic and Treatment Approach

Begin with ankle-brachial index (ABI) measurement and duplex ultrasound to establish the diagnosis of arterial compression, followed by advanced imaging (CTA or MRA) to define the anatomical location and severity of compression before considering revascularization.

Initial Diagnostic Work-Up

First-Line Noninvasive Testing

The diagnostic evaluation should start with:

• Resting ABI measurement in both legs to confirm peripheral arterial disease (PAD) and establish baseline values 1
• Duplex ultrasound of the lower extremities to diagnose anatomic location and degree of stenosis 1
• Segmental pressure examination and pulse volume recordings to localize the level of arterial obstruction 2

Critical clinical distinction: Tibial artery occlusive disease specifically produces calf pain or foot pain and numbness, distinguishing it from more proximal lesions 2. The anatomic site of arterial stenosis correlates with specific leg symptoms—iliac disease causes hip/buttock/thigh pain, while femoral-popliteal disease typically causes calf pain.

Advanced Imaging When Revascularization is Considered

Once noninvasive testing confirms significant arterial disease, proceed with anatomic imaging:

• CTA of pelvis with runoff (rating 8/9 - usually appropriate) provides fast, detailed visualization of the entire arterial tree 3, 4
• MRA with gadolinium enhancement is equally useful for diagnosing location and degree of stenosis, particularly when CTA is contraindicated 1
• Contrast angiography remains the gold standard when revascularization is contemplated, providing the most detailed anatomic information 1

Important caveat: In younger, otherwise healthy patients with exertional leg symptoms and numbness, consider vascular compression syndromes (popliteal artery entrapment, thoracic outlet syndrome) rather than atherosclerotic disease 5, 6, 7. These require imaging in both neutral and provocative positions using Doppler ultrasound or MRA.

Severity Assessment

Hemodynamic thresholds that guide management:

• ABI <0.6 indicates significant ischemia affecting wound healing potential 8
• Toe pressure <30 mmHg or TcPO₂ <30 mmHg indicates severely impaired healing 8
• ABI >0.6 requires additional toe pressure or TcPO₂ measurement for accurate assessment 8

Treatment Algorithm

Medical Management (All Patients)

Antiplatelet therapy is foundational 9:

• Single antiplatelet therapy with aspirin (75-325 mg) or clopidogrel (75 mg) for symptomatic lower extremity PAD 9
• For high-risk patients (polyvascular disease, diabetes, heart failure, renal insufficiency, or post-revascularization): rivaroxaban 2.5 mg twice daily plus aspirin 80-100 mg daily provides superior protection against major adverse cardiovascular and limb events 9

Contraindications to rivaroxaban combination: Strong CYP3A4 or p-glycoprotein interactions, recent stroke (<1 month), any previous hemorrhagic stroke, or eGFR <15 mL/min 9

Statin therapy is mandatory to improve walking distance and reduce cardiovascular risk 10, 1

Revascularization Indications

Consider revascularization when 10:

1. Daily life activities remain significantly compromised despite 3 months of supervised exercise therapy
2. Patient has disabling symptoms substantially altering quality of life
3. Lesion anatomy suggests low procedural risk with high probability of success

Revascularization Strategy by Anatomic Location

Aorto-iliac lesions 3, 10:

• Short stenosis/occlusion (<5 cm): Primary stenting or angioplasty (rating 8/9) with excellent long-term patency (>90% at 5 years)
• TASC B lesions (short-segment occlusion): Primary angioplasty or stenting (rating 8/9)
• TASC C/D lesions (extensive disease): Consider surgical revascularization (rating 7/9) or primary stenting (rating 8/9) based on anatomy

Femoral-popliteal lesions 10:

• Endovascular therapy is reasonable for focal disease, though long-term patency remains challenging (43-66% at 5 years with conventional/drug-eluting stents)
• Surgical bypass with great saphenous vein achieves superior long-term patency (>80% at 5 years above-knee)

Post-Revascularization Antithrombotic Therapy

After elective endovascular revascularization 9:

• Rivaroxaban 2.5 mg twice daily plus aspirin 80-100 mg daily (preferred)
• Alternative: DAPT with aspirin plus clopidogrel for at least 1 month if rivaroxaban contraindicated

After elective open revascularization 9:

• Rivaroxaban 2.5 mg twice daily plus aspirin 80-100 mg daily (strong recommendation)
• Consider VKA for infrainguinal bypass with high-risk features (poor conduit quality, long conduit, disadvantaged runoff)

Common Pitfalls to Avoid

1. Don't dismiss atypical symptoms: Numbness from tibial artery disease is a legitimate presentation of PAD, not just "pseudoclaudication" 2
2. Don't skip toe pressures when ABI is 0.6-0.9: This range has limited predictive value and requires additional testing 8
3. Don't forget to image below-the-knee vessels: Complete evaluation requires visualization of tibial and pedal arteries when revascularization is planned 8
4. Don't overlook compression syndromes in young patients: Standard atherosclerotic workup may miss popliteal entrapment or thoracic outlet syndrome 5, 7
5. Don't use rivaroxaban as monotherapy for atrial fibrillation: The 2.5 mg twice daily dose is insufficient for stroke prevention 9

Surveillance After Revascularization

For venous bypass grafts 1:

• Duplex ultrasound at 3,6, and 12 months, then yearly
• Include interval vascular history, resting ABIs, and physical examination

For endovascular procedures 1:

• Exercise ABIs and arterial imaging at regular intervals may be considered for surveillance